FOLH1 and prostate carcinoma: In a study by Nonnekens et.al, two molecules of PSMA I&T (chemical structure) and JVZ-008 (nanobody structure) that had a good binding efficacy to PSMA were selected and attached to an α-emitting radionuclides (213Bi) for greater effect on prostate cancer cells.